Table 3.
Hazard ratios (HRs) for the association between the methylation levels at the ten most significant variably methylated regions (VMRs) and overall survival in the Melbourne Collaborative Cohort Study (MCCS) and The Cancer Genome Atlas (TCGA) dataset
| MCCS | TCGA | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjusted for age | Adjusted for age and stage | Adjusted for age | Adjusted for age and stage | |||||||||||
| Gene* | Averagemethylation** | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | Average methylation** | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P |
| APC | 39.1 | 1.28 (1.07–1.53) | 0.01 | 1.24 (1.04–1.47) | 0.02 | 1.24 (1.04–1.49) | 0.01 | 35.9 | 1.16 (0.89–1.51) | 0.28 | 1.12 (0.86–1.44) | 0.41 | 1.06 (0.82–1.38) | 0.63 |
| TMEM101 | 39.6 | 1.21 (1.00–1.48) | 0.06 | 1.19 (0.98–1.44) | 0.08 | 1.22 (0.99–1.51) | 0.06 | 39 | 1.13 (0.77–1.66) | 0.52 | 1.12 (0.78–1.60) | 0.54 | 1.27 (0.87–1.85) | 0.21 |
| ISM1 | 22.8 | 1.34 (0.97–1.85) | 0.07 | 1.02 (0.76–1.38) | 0.89 | 0.90 (0.65–1.26) | 0.54 | 19.2 | 1.48 (0.91–2.41) | 0.11 | 1.38 (0.80–2.37) | 0.25 | 1.48 (0.86–2.54) | 0.15 |
| ASCL2 | 44.4 | 1.16 (0.81–1.65) | 0.42 | 0.93 (0.66–1.31) | 0.69 | 0.99 (0.71–1.38) | 0.95 | 44.6 | 1.28 (0.74–2.20) | 0.38 | 1.17 (0.68–2.02) | 0.57 | 1.44 (0.81–2.57) | 0.22 |
| HIST3H2A | 20.1 | 1.28 (1.02–1.62) | 0.03 | 1.08 (0.86–1.35) | 0.53 | 1.03 (0.82–1.29) | 0.78 | 20.1 | 1.35 (1.00–1.83) | 0.05 | 1.28 (0.94–1.73) | 0.12 | 1.23 (0.90–1.68) | 0.18 |
| NKX6 | 29 | 1.25 (0.98–1.60) | 0.07 | 1.06 (0.83–1.35) | 0.63 | 1.01 (0.79–1.29) | 0.91 | 30.2 | 2.06 (1.32–3.21) | 0.001 | 1.88 (1.21–2.92) | 0.01 | 2.01 (1.28–3.17) | 0.002 |
| HCG4P3 | 29.1 | 1.24 (0.93–1.67) | 0.14 | 1.13 (0.84–1.53) | 0.41 | 1.25 (0.91–1.72) | 0.16 | 31.1 | 2.04 (1.32–3.15) | 0.001 | 1.80 (1.13–2.85) | 0.01 | 1.69 (1.05–2.72) | 0.03 |
| HES5 | 19 | 1.11 (0.88–1.40) | 0.38 | 1.11 (0.88–1.40) | 0.37 | 1.13 (0.89–1.42) | 0.29 | 20.9 | 1.26 (0.88–1.80) | 0.21 | 1.15 (0.80–1.65) | 0.45 | 1.13 (0.76–1.68) | 0.53 |
| CELF2 | 33.4 | 1.30 (1.07–1.58) | 0.01 | 1.12 (0.93–1.36) | 0.23 | 1.13 (0.93–1.36) | 0.21 | 35 | 1.50 (1.06–2.12) | 0.02 | 1.44 (1.01–2.05) | 0.04 | 1.51 (1.07–2.13) | 0.02 |
| EFCAB4B | 32.8 | 1.01 (0.83–1.23) | 0.88 | 0.96 (0.80–1.15) | 0.63 | 0.99 (0.83–1.19) | 0.99 | 34.5 | 1.41 (1.05–1.89) | 0.02 | 1.32 (0.98–1.78) | 0.07 | 1.25 (0.93–1.67) | 0.14 |
*Gene: Gene associated with the variably methylated regions (VMRs), most of the VMRs were located in the promoter region of the genes, **Average methylation: Average methylation level (beta-value) of the samples across the VMRs, HR hazard ratio, CI confidence interval